Actively Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Led by Dizal (Jiangsu) Pharmaceutical Co., Ltd. · Updated on 2025-12-24
66
Participants Needed
15
Research Sites
223 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
CONDITIONS
Official Title
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 years or older
- ECOG performance status between 0 and 2, with a life expectancy of at least 6 months
- Confirmed newly diagnosed or treatment-nafve CLL/SLL with indication for treatment
- For SLL patients, at least one measurable lesion
- Adequate bone marrow and organ function
- Willingness to follow contraceptive restrictions
You will not qualify if you...
- Previous or current treatments not allowed by the study protocol
- Unresolved drug-related adverse events greater than grade 1
- Known or suspected Richter's transformation or prolymphocytic leukemia
- Central nervous system involvement
- Active infection
- Severe cardiac or pulmonary abnormalities
- Poorly controlled autoimmune anemia or thrombocytopenia
- Poorly controlled gastrointestinal disorders or other systemic diseases preventing medication absorption
- History of other cancers within the past 3 years
- Allergy to study drugs, ingredients, xanthine oxidase inhibitors, or rasburicase
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Anhui Provincial Cancer Hospital
Hefei, Anhui, China, 230031
Actively Recruiting
2
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191
Actively Recruiting
3
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510280
Actively Recruiting
4
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515
Actively Recruiting
5
Henan Cancer Hospital
Zhengzhou, Henan, China, 450008
Actively Recruiting
6
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430022
Actively Recruiting
7
Yichang Central People's Hospital
Yichang, Hubei, China, 443003
Actively Recruiting
8
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Actively Recruiting
9
The First People's Hospital of Changzhou
Changzhou, Jiangsu, China, 213003
Actively Recruiting
10
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China, 226001
Actively Recruiting
11
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
Actively Recruiting
12
The First Bethune Hospital of Jilin University
Changchun, Jilin, China, 130021
Not Yet Recruiting
13
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004
Not Yet Recruiting
14
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
15
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
Research Team
L
Ling Zhou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here